{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T10:13:38Z","timestamp":1778753618932,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Terumo Blood and Cell Technologies"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07022-z","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:10:29Z","timestamp":1777691429000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world use of pharmacologic therapy and chronic blood transfusion in sickle cell disease, 2014\u20132021"],"prefix":"10.1007","volume":"105","author":[{"given":"Kangho","family":"Suh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terri V.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Haubner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darrell J.","family":"Triulzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico M.","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"7022_CR1","unstructured":"Centers for Disease Control and Prevention (2024) Data and statistics on sickle cell disease. https:\/\/www.cdc.gov\/sickle-cell\/data\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/ncbddd\/sicklecell\/data.html. Accessed July 15, 2025"},{"key":"7022_CR2","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","volume":"4","author":"GJ Kato","year":"2018","unstructured":"Kato GJ, Piel FB, Reid CD et al (2018) Sickle cell disease. Nat Rev Dis Primers 4:18010","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"7022_CR3","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1377\/hlthaff.2023.00527","volume":"42","author":"C Horrow","year":"2023","unstructured":"Horrow C, Kesselheim AS (2023) Confronting High Costs And Clinical Uncertainty: Innovative Payment Models For Gene Therapies. Health Aff (Millwood) 42(11):1532\u20131540","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"7022_CR4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.hemonc.2019.12.004","volume":"13","author":"L Oevermann","year":"2020","unstructured":"Oevermann L, Sodani P (2020) Status quo of allogeneic stem cell transplantation for patients with sickle cell disease using matched unrelated donors. Hematol Oncol Stem Cell Ther 13(2):116\u2013119","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"2","key":"7022_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1182\/bloodadvances.2019001143","volume":"4","author":"ST Chou","year":"2020","unstructured":"Chou ST, Alsawas M, Fasano RM et al (2020) American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv 4(2):327\u2013355","journal-title":"Blood Adv"},{"issue":"11","key":"7022_CR6","doi-asserted-by":"publisher","first-page":"e2344546","DOI":"10.1001\/jamanetworkopen.2023.44546","volume":"6","author":"TV Newman","year":"2023","unstructured":"Newman TV, Yang J, Suh K, Jonassaint CR, Kane-Gill SL, Novelli EM (2023) Use of Disease-Modifying Treatments in Patients With Sickle Cell Disease. JAMA Netw Open 6(11):e2344546","journal-title":"JAMA Netw Open"},{"issue":"3","key":"7022_CR7","doi-asserted-by":"publisher","first-page":"e30152","DOI":"10.1002\/pbc.30152","volume":"70","author":"AY Tang","year":"2023","unstructured":"Tang AY, Zhou M, Maillis AN, Lai KW, Lane PA, Snyder AB (2023) Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004\u20132019. Pediatr Blood Cancer 70(3):e30152","journal-title":"Pediatr Blood Cancer"},{"key":"7022_CR8","unstructured":"Bazell C, Dieguez G, Ferro C, Mirchandani H (2019) A claims-based analysis of sickle cell disease: Prevalence, disease complications, and costs. Milliman Res Rep 1\u201327. https:\/\/www.milliman.com\/en\/insight\/a-claimsbased-analysis-of-sickle-cell-disease-prevalence-disease-complications-and-cos. Accessed 10 September 2025"},{"issue":"12","key":"7022_CR9","doi-asserted-by":"publisher","first-page":"e28703","DOI":"10.1002\/pbc.28703","volume":"67","author":"SD Grosse","year":"2020","unstructured":"Grosse SD, Green NS, Reeves SL (2020) Administrative data identify sickle cell disease: A critical review of approaches in U.S. health services research. Pediatr Blood Cancer 67(12):e28703","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"7022_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40266-023-01014-8","volume":"40","author":"CI Oyedeji","year":"2023","unstructured":"Oyedeji CI, Hodulik KL, Telen MJ, Strouse JJ (2023) Management of Older Adults with Sickle Cell Disease: Considerations for Current and Emerging Therapies. Drugs Aging 40(4):317\u2013334","journal-title":"Drugs Aging"},{"issue":"1","key":"7022_CR11","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ajh.21880","volume":"86","author":"M Treadwell","year":"2011","unstructured":"Treadwell M, Telfair J, Gibson RW, Johnson S, Osunkwo I (2011) Transition from pediatric to adult care in sickle cell disease: establishing evidence-based practice and directions for research. Am J Hematol 86(1):116\u2013120","journal-title":"Am J Hematol"},{"issue":"10","key":"7022_CR12","doi-asserted-by":"publisher","first-page":"e2128971","DOI":"10.1001\/jamanetworkopen.2021.28971","volume":"4","author":"JG Mathias","year":"2021","unstructured":"Mathias JG, Nolan VG, Klesges LM et al (2021) Hydroxyurea Use After Transitions of Care Among Young Adults With Sickle Cell Disease and Tennessee Medicaid Insurance. JAMA Netw Open 4(10):e2128971","journal-title":"JAMA Netw Open"},{"issue":"17","key":"7022_CR13","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1182\/blood-2018-03-818161","volume":"132","author":"SL Thein","year":"2018","unstructured":"Thein SL, Howard J (2018) How I treat the older adult with sickle cell disease. Blood 132(17):1750\u20131760","journal-title":"Blood"},{"issue":"7","key":"7022_CR14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/hec.3899","volume":"28","author":"M Li","year":"2019","unstructured":"Li M, Basu A, Bennette CS, Veenstra DL, Garrison LP (2019) Do cancer treatments have option value? Real-world evidence from metastatic melanoma. Health Econ 28(7):855\u2013867","journal-title":"Health Econ"},{"issue":"2","key":"7022_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/j.seminhematol.2020.07.007","volume":"57","author":"D Sharma","year":"2020","unstructured":"Sharma D, Ogbenna AA, Kassim A, Andrews J (2020) Transfusion support in patients with sickle cell disease. Semin Hematol 57(2):39\u201350","journal-title":"Semin Hematol"},{"issue":"5","key":"7022_CR16","doi-asserted-by":"publisher","first-page":"103556","DOI":"10.1016\/j.transci.2022.103556","volume":"61","author":"LR Wallace","year":"2022","unstructured":"Wallace LR, Thibodeaux SR (2022) Transfusion support for patients with sickle cell disease. Transfus Apher Sci 61(5):103556","journal-title":"Transfus Apher Sci"},{"issue":"11","key":"7022_CR17","doi-asserted-by":"publisher","first-page":"E341","DOI":"10.1002\/ajh.27074","volume":"98","author":"M Di Mauro","year":"2023","unstructured":"Di Mauro M, El Hoss S, Nardo-Marino A et al (2023) Males with sickle cell disease have higher risks of cerebrovascular disease, increased inflammation, and a reduced response to hydroxyurea. Am J Hematol 98(11):E341\u2013e344","journal-title":"Am J Hematol"},{"issue":"10","key":"7022_CR18","doi-asserted-by":"publisher","first-page":"e0258638","DOI":"10.1371\/journal.pone.0258638","volume":"16","author":"RV Masese","year":"2021","unstructured":"Masese RV, Bulgin D, Knisely MR et al (2021) Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium. PLoS ONE 16(10):e0258638","journal-title":"PLoS ONE"},{"issue":"5","key":"7022_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/pds.4291","volume":"27","author":"J Han","year":"2018","unstructured":"Han J, Zhou J, Saraf SL, Gordeuk VR, Calip GS (2018) Characterization of opioid use in sickle cell disease. Pharmacoepidemiol Drug Saf 27(5):479\u2013486","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"7022_CR20","first-page":"94","volume":"7","author":"HA Kang","year":"2020","unstructured":"Kang HA, Barner JC, Richards KM, Bhor M, Paulose J, Kutlar A (2020) Association between Vaso-occlusive Crises and Opioid Prescriptions among Patients with Sickle Cell Disease: A Retrospective Claims-based Study. J Health Econ Outcomes Res 7(1):94\u2013101","journal-title":"J Health Econ Outcomes Res"},{"key":"7022_CR21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.21037\/aob-21-67","volume":"7","author":"YC Tanhehco","year":"2022","unstructured":"Tanhehco YC, Shi PA, Schwartz J (2022) Transfusion therapy in sickle cell disease. Annals Blood 7:9","journal-title":"Annals Blood"},{"issue":"8","key":"7022_CR22","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1111\/trf.14806","volume":"58","author":"E Biller","year":"2018","unstructured":"Biller E, Zhao Y, Berg M et al (2018) Red blood cell exchange in patients with sickle cell disease-indications and management: a review and consensus report by the therapeutic apheresis subsection of the AABB. Transfusion 58(8):1965\u20131972","journal-title":"Transfusion"},{"issue":"1","key":"7022_CR23","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1182\/hematology.2023000498","volume":"2023","author":"S Kelly","year":"2023","unstructured":"Kelly S (2023) Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease. Hematol Am Soc Hematol Educ Program 2023(1):646\u2013652","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"7","key":"7022_CR24","doi-asserted-by":"publisher","first-page":"E179","DOI":"10.1002\/ajh.26940","volume":"98","author":"JW Jacobs","year":"2023","unstructured":"Jacobs JW, Diaz M, Arevalo Salazar DE et al (2023) United States blood pricing: A cross-sectional analysis of charges and reimbursement at 200 US hospitals. Am J Hematol 98(7):E179\u2013e182","journal-title":"Am J Hematol"},{"key":"7022_CR25","unstructured":"Bradt P, Spackman E, Synnott P et al (2020) Crizanlizumab, voxelotor, and L-glutamine for sickle cell disease: Effectiveness and value. Institute for Clinical and Economic Review. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_SCD_Evidence-Report_031220-FOR-PUBLICATION.pdf. Published Janury 23, Accessed 1\/28\/2026"},{"issue":"6","key":"7022_CR26","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1159\/000369513","volume":"41","author":"SA Campbell-Lee","year":"2014","unstructured":"Campbell-Lee SA, Kittles RA (2014) Red blood cell alloimmunization in sickle cell disease: listen to your ancestors. Transfus Med Hemother 41(6):431\u2013435","journal-title":"Transfus Med Hemother"},{"issue":"4","key":"7022_CR27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000491883","volume":"45","author":"J Khan","year":"2018","unstructured":"Khan J, Delaney M (2018) Transfusion Support of Minority Patients: Extended Antigen Donor Typing and Recruitment of Minority Blood Donors. Transfus Med Hemother 45(4):271\u2013276","journal-title":"Transfus Med Hemother"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07022-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07022-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07022-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:23:05Z","timestamp":1778750585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07022-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["7022"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07022-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Disclosure of potential conflicts of interest: AH and MA are employed by Terumo Blood and Cell Technologies. DJT reports receiving consulting fees from Fresenius Kabi. EMN reports being an advisory panel member and consulting work with Novo Nordisk.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AH and MA are employed by Terumo Blood and Cell Technologies. DJT reports receiving consulting fees from Fresenius Kabi. EMN reports being an advisory panel member and consulting work with Novo Nordisk.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"282"}}